Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

University of Pennsylvania · with GlaxoSmithKline, Boehringer Ingelheim · NCT07444203

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
200
US sites recruiting
1
Study start
November 12, 2025
Record last updated
March 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care.

The main questions this study aims to answer are:

  • Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them?
  • Are these kidney tissue patterns linked with how kidney health changes over time?

Researchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines.

Participants will

Let researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time

Being studied: Sodium-glucose cotransporter 2 inhibitors (SGLT2i); Renin-angiotensin-aldosterone system blockade; Glucagon-like peptide-1 receptor agonists (GLP 1 RA); Mineralocorticoid Receptor Antagonists(MRAs)

Conditions: Diabetic Nephropathies; Kidney Diseases; Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age ≥18 years
  • eGFR ≥10 ml/min/1.73 m2 based on the 2021 race-free CKD-EPI equation13
  • Underwent a clinically indicated kidney biopsy, living donor biopsy, or nephrectomy (non-tumor adjacent tissue available).
  • Able and willing to provide informed consent for release of one pathology and clinical data abstraction.

Exclusion Criteria

  • Inability to provide informed consent.
  • Archived biopsy or surgical tissue unavailable for slide preparation.
  • Any local institutional policy that prohibits release of H\&E slides for research.

Recruiting US locations

  • Penn Presbyterian Medical Center

    Philadelphia, PA 19104

    Site contact: Gaia Coppock, MD · 2673030158 · Gaia.Coppock@pennmedicine.upenn.edu

Study contacts (from the official record)

  • Gaia Coppock, MD · 2673030158 · Gaia.Coppock@pennmedicine.upenn.edu
  • Mohammed Al Dulaimee, BS · 5853589733 · mohammed.aldulaimee@pennmedicine.upenn.edu
All diabetes studies in Pennsylvania →
Transformative Research in Diabetic Nephropathy 2.0 (NCT07444203) | Bored Studies